Results 161 to 170 of about 167,695,866 (259)

Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model

British Journal of Clinical Pharmacology, EarlyView.
Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić, Ivana Stević, Elvira Meni Maria Gkrinia, Dinko Vitezić, Slobodan Janković   +4 more
wiley   +1 more source

The (implicit) cost of equity trading at the Oslo Stock Exchange. What does the data tell us? [PDF]

We empirically investigate the costs of trading equity at the Oslo Stock Exchange in the period 1980--2008. We show the time series evolution of different measures of (implicit) trading costs: bid/ask spreads, the Roll(1984) measure and the Lesmond et al
Ødegaard, Bernt Arne
core  

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

British Journal of Clinical Pharmacology, EarlyView.
Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay, Amandine Manon, Hunter Stephens, S. Y. Amy Cheung, Bart de Keizer, Erik T. te Beek   +5 more
wiley   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Cost of equity in Singapore.

, 2010
Our paper examines the cost of equity in the Singapore market using five different pricing models, namely CAPM, CAPM with size premium, Build-up method, Fama and French three-factor model, and Carhart four-factor model. We seek to find the firm-specific,
Foo, Qiao Yun., Teng, Sheng Hua., Ng, Cassie Yi Ting.   +2 more
core  

Equity-focused investment strategies to reduce maternal mortality in the Philippines: a subnational analysis using EQUIST. [PDF]

J Glob Health
Whitley K, Lebedeva P, Christie AC, Sim A, Thompson D, Hukpati S, Balaji L.   +6 more
europepmc   +1 more source

Precision medicine in paediatrics: Progress and priorities

British Journal of Clinical Pharmacology, EarlyView.
Precision medicine is revolutionizing personalized healthcare, advancing both diagnostics and therapeutics at an unprecedented pace. Reviewing the paediatric applications of pharmacometrics, pharmacogenomics and advanced therapy medicinal products highlights not only the relevance of these exciting innovations to frontline care but also the significant
Nicola Husain, Claire Booth, Joseph F. Standing, Charlotte I. S. Barker   +3 more
wiley   +1 more source

Health services research and advocacy in US cancer care: pathways from evidence to implementation. [PDF]

Lancet Reg Health Am
Gorantla N, George M, Swami N, Patel MS, Wu JF, Budhu JA, Yerramilli D, Sichta L, Runfola S, Clauer JS, Studebaker Freeman T, Jain B, Feliciano EJG, Lapen K, Chino F, Moraes FY, McBride SM, Nguyen PL, Lam MB, Lee NY, Dee EC.   +20 more
europepmc   +1 more source

Trends in publicly subsidized and private access to GLP‐1 medicines indicated for type 2 diabetes in Australia, 2020–2025

British Journal of Clinical Pharmacology, EarlyView.
Aims GLP‐1 medicines provide substantial cardio‐renal benefits for type 2 diabetes (T2D) and are increasingly used for weight loss. Most high‐income countries subsidize access for T2D with restrictions; use outside of these restrictions occurs through private prescriptions. Despite strong consumer demand, the extent of private access to GLP‐1 medicines
Michael O. Falster, Juliana de Oliveira Costa, Tamara Y. Milder, Joanne Carson, Cade Shadbolt, Brendon L. Neuen, Clare Arnott, Andrew Wilson, Min Jun, Nicole Pratt, Sallie‐Anne Pearson   +10 more
wiley   +1 more source

Health System Integration and Equity in Type 2 Diabetes Prevention: A Comparative Policy Analysis of Seven National Guidelines. [PDF]

J Eval Clin Pract
Marfo R, Miezah D, Ansong R, Abubakari M, Kyei EF.   +4 more
europepmc   +1 more source